Neuros Medical, a neuromodulation company, is set to begin a pilot clinical trial to assess its high frequency Electrical Nerve Block technology following an Investigational Device Exemption (IDE) approval from the US Food and Drug Administration.

The patented Electrical Nerve Block technology is designed to eliminate chronic amputation pain, chronic post-surgical pain, chronic migraine, and trigeminal neuralgia.

The approval is based on the company’s first-in-man feasibility study wherein four out of five patients with chronic amputation pain reported pain reduction, sometimes minimizing pain scores to zero.

Neuros Medical President and CEO Jon J. Snyder said they are excited about the IDE approval and look forward to commencing the pilot study to provide longer term safety and efficacy data of Electrical Nerve Block technology in a larger set of patients.